FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

JPMorgan Pilots Software to Monitor Junior Bankers’ Working Hours

New initiative aims to enhance oversight of junior employee hours worked.Highlights: JPMorgan tests software to monitor working hours...
FinTech

Goldman Sachs to Implement Performance-Based Staff Cuts in April

The bank plans restructuring amidst shifting financial landscape.Highlights: Goldman Sachs plans performance-based staff cuts in April.The restructuring aims...
FinTech

Nasdaq Secures SEC Approval for Trading Tokenized Securities

This marks a significant advancement in digital asset trading.Highlights: Nasdaq gains SEC approval for trading tokenized securities.This approval...
FinTech

Aveni Launches Agentic AI Council to Enhance AI Ethics

New council aims to guide ethical AI development and deployment strategies.Highlights: Aveni establishes the Agentic AI Council for...